At the European Cancer Congress (ECC) 2015, André Robidoux, MD, FRCSC, of Centre Hospitalier de l’Université de Montréal, Montreal, Canada, discusses the results to date for Trial Assigning IndividuaLized Options for Treatment (TAILORx), which is a prospective phase 3 clinical trial evaluating the utility of the Oncotype DX® Breast Cancer Assay to guide adjuvant treatment decisions in patients with ER-positive, HER2-negative, node-negative breast cancer.
Promising outcomes at 5 years were reported in patients with a low Oncotype DX Recurrence Score® (RS) result, which suggests this population may be safely spared of chemotherapy. The evaluation continues in the study group comprising patients with an intermediate RS result who are randomised to receive hormonal treatment alone or a combination of hormonal treatment and chemotherapy.
This content is supported by Genomic Health, Inc.
